Stage 2 squamous cell carcinoma of the skin is curable in most cases. At this stage, the cancer has not spread to lymph nodes or distant organs, and the five-year survival rate for early-detected squamous cell carcinoma is 99 percent. Stage 2 does mean the tumor has at least one high-risk feature, such as growing into deeper layers of skin or invading nearby nerves, so treatment and follow-up are more involved than for a stage 1 diagnosis.
What Makes It Stage 2
Squamous cell carcinoma is classified as stage 2 when the tumor is still localized (confined to the skin) but displays features that raise concern. These can include a tumor larger than 2 centimeters, invasion into the deeper layers of skin, or spread along nearby nerves, a pattern called perineural invasion. The key distinction from stage 1 is the presence of at least one of these high-risk characteristics. The key distinction from stage 3 or 4 is that the cancer has not reached lymph nodes or other parts of the body.
Skin vs. Lung Squamous Cell Carcinoma
If your diagnosis involves the lung rather than the skin, the outlook is very different. Stage 2 lung squamous cell carcinoma falls roughly into the “localized” or early “regional” category, where five-year survival rates range from about 40 to 67 percent for non-small cell lung cancer. These are meaningful survival rates, but they are substantially lower than for cutaneous (skin) squamous cell carcinoma. The rest of this article focuses on the skin form, which is far more common and what most people searching this term have been diagnosed with.
How Stage 2 Skin SCC Is Treated
Surgery is the primary treatment. The goal is to remove the entire tumor with clear margins, meaning no cancer cells are found at the edges of the removed tissue. Two main approaches are used.
Mohs micrographic surgery is considered the preferred technique for high-risk tumors. During the procedure, the surgeon removes thin layers of tissue and examines each one under a microscope before taking more, continuing until no cancer cells remain. This approach checks 100 percent of the surgical margin, both the edges and the deep surface. In studies comparing outcomes, patients treated with Mohs surgery had a local recurrence rate of 9.6 percent, compared to 19.8 percent with standard wide excision. Rates of the cancer spreading to lymph nodes were also lower: 11 percent with Mohs versus nearly 18 percent with wide excision.
Wide local excision, where the surgeon removes the tumor along with a margin of surrounding healthy tissue, is the alternative when Mohs is not available. For high-risk tumors, wider margins are taken, and the NCCN recommends that complete assessment of all deep and peripheral margins still be performed whenever possible, even outside of Mohs. If only partial margin assessment can be done, surgeons compensate by removing a larger border of tissue.
Radiation therapy is sometimes used after surgery when certain risk factors are present, such as cancer found at or near the surgical margins, perineural invasion, or other features that suggest a higher chance of recurrence. It can also serve as the primary treatment for patients who cannot undergo surgery.
Cure Rates and Recurrence Risk
Most stage 2 squamous cell carcinomas are cured with surgery alone. The overall five-year survival for squamous cell carcinoma caught before it spreads beyond the skin is 99 percent, and stage 2 falls within that category. Once squamous cell carcinoma has spread beyond the skin, the five-year survival drops below 50 percent, which is why treating stage 2 thoroughly matters: the goal is to eliminate the cancer before it has a chance to advance.
Recurrence risk depends on several factors. Tumors with perineural invasion, poorly differentiated cells (meaning the cancer cells look very abnormal under a microscope), or location on the ear, lip, or temple tend to recur more often. Immune suppression is another significant factor. Patients who have received an organ transplant or who take medications that suppress the immune system face a higher disease burden and worse outcomes compared to immunocompetent patients with similar tumors, even when treated with the same combination of therapies.
The surgical technique also affects recurrence. In comparative data, any recurrence (local, nodal, or distant) occurred in 15.8 percent of patients treated with Mohs surgery versus 32 percent of those treated with wide local excision. Disease-specific death rates were 7.1 percent and 17.5 percent, respectively. These numbers highlight how much margin-assessment technique influences long-term outcomes for high-risk tumors.
What Follow-Up Looks Like
Because stage 2 is classified as high-risk, follow-up visits are more frequent than for a low-risk skin cancer. For the first two years after treatment, expect skin checks and physical exams every three to six months. If no new cancer develops during that window, visits space out to every six to twelve months for the next three years. The first two years are the most critical period for catching any recurrence early.
Very high-risk cases follow a similar but slightly tighter schedule: exams every three to six months for the first two years, then every six months for another three years. During these visits, your doctor will examine the surgical site, check nearby lymph nodes by touch, and do a full skin examination to look for new lesions. Imaging scans are not routine for localized disease but may be ordered if there are concerning symptoms or findings on exam.
After the initial five-year monitoring period, annual skin checks are still recommended for life. Having had one squamous cell carcinoma increases your risk of developing another, so ongoing surveillance is part of the long-term plan regardless of how well the first treatment went.